Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180675 | 0.85 | DYRK1B (0.40) | DYRK1BNR4A2DOT1LAXLPRKCI | |
| SCHEMBL10123872 | 0.84 | DYRK1B (0.37) | DYRK1BNR4A2DOT1LAXLPRKCI | |
| SCHEMBL10106297 | 0.83 | DYRK1B (0.39) | DYRK1BNR4A2DOT1LAXLPRKCI | |
| SCHEMBL16288863 | 0.81 | SMN1; SMN2 (0.46) | NR4A2KDM4EMAPTALDH1A1CYP1A2 | |
| SCHEMBL10119031 | 0.80 | DYRK1B (0.35) | DYRK1BNR4A2DOT1LAXLPRKCI | |
| SCHEMBL16288862 | 0.80 | KDM4E (0.31) | NR4A2KDM4EMAPTMAPK1HTR1A | |
| SCHEMBL17059451 | 0.78 | KDM4E (0.35) | KDM4EMAPK1 | |
| SCHEMBL17059468 | 0.77 | SRC (0.58) | KDM4EMAPTMAPK1PIK3CAGAK | |
| SCHEMBL27465861 | 0.76 | KMT5B (0.35) | DYRK1BNR4A2AXLPRKCIKDM4E | |
| SCHEMBL27470369 | 0.76 | ALOX15 (0.37) | DYRK1BNR4A2AXLPRKCIMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2009080200-A1 | NOVEL SULPHOXIMIDE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080200-A1 | NOVEL SULPHOXIMIDE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072502-A1 | Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-24 | — | — | EP | disclosed |
| EP-2072502-A1 | Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | DYRK1B 175/4885NR4A2 2212/4885DOT1L 119/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | DYRK1B 175/4885NR4A2 2212/4885DOT1L 119/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | DYRK1B 175/4885NR4A2 2212/4885DOT1L 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.